Highlights from the WCLC24 Day 3
The WCLC24 is taking place at the San Diego Convention Center from September 7 to 10, 2024.
The International Association for the Study of Lung Cancer (IASLC) is a global, multidisciplinary organization committed to the eradication of all forms of lung cancer. The IASLC unites a diverse group of professionals – including medical, surgical, and radiation oncologists, as well as nurses, basic scientists, pathologists, radiologists, pulmonologists, statisticians, patient advocates, patients, and caregivers in– its mission to advance the science of lung cancer and enhance patient care.
Organized by the International Association for the Study of Lung Cancer (IASLC), this major conference is gathering leading experts, researchers, and oncologists to present and discuss the latest advancements in lung cancer research, treatment, and personalized therapies, fostering collaborative efforts towards overcoming the challenges of lung cancer.
Here are some Highlights from the WCLC24 Day 3:
“WCLC24 Presidential II
Superb discussion by Alfredo Addeo of FURTHER trial, next steps:
- Response by compound PACC, single PACC, atypical mtns
- Role of co-mtns
- Monitor tox signal Congrats to authors- an important study, in an emerging subset of EGFR+ NSCLC”
“There’s something really special about mentoring the future generation on minority oncologists Proud of your drive and achievements Nehemias Guevara-Rodriguez.
Presenting the work on lung cancer in pregnancy.”
“Dr. Joshua Reuss presenting the data on CEACAM, MET, and TROP2 ADCs. Many great questions we still have yet to answers here.”
“Dr. Xiuning Le presents SOHO-01, BAY2927088 (oral TKI) in HER2 mut. Lung Cancer previously treatment with chemotherapy
-Promising ORR 72.1% with 1 CR
-mPFS 7.5 mo
-AEs: 86% diarrhea (G1-2), 25% with G3+ diarrhea
-31.8% required dose reductions and 3 patients had to discontinue due to TRAEs”
“Stay Tuned Lung Cancer Considered in Arabic IASLC.
Thank you Stephen V Liu.
The 4 episodes: Highlights from WCLC24, Chemo immunotherapy, Training the future thoracic oncologist and Arab Women in thoracic oncology.”
“Meeting a living legend: Rafael Rossell has been a long standing model of a physician-scientist and a paradigm of innovator, mentor, discovery spirit and scientific excellence. We owe a lot to him !!”
“Had a fun time today participating in a roundtable interview with DXY Media. The focus was on discussing career development opportunities within IASLC.
A topic close to my heart and important for early career investigators to be aware of. My esteemed colleagues Dr. Matthew Smeltzer, Dr. Wenzhao Zhong, Dr. Chunxue Bai, and I highlight our journey and the multiple avenues within IASLC to find mentorship, funding, and career development opportunities.”
“Spoiler alert: we can (and probably need to!) separate clinical outcomes from our self-worth WITHOUT lessening our commitment to deliver high-quality care One litmus test is to ask if we are extending ourselves the same degree of compassion we hope to offer to our patients.”
“As we wrap up another incredible day at WCLC24, take a look at some of our favorite moments
From insightful sessions to impactful discussions and everything in between, it’s been a day full of learning, connections, and inspiration.”
“Monday at WCLC24:
Mark Lewis will offer strategies for navigating challenging patient outcomes during a Health and Wellbeing Session. Read a preview in ILCN.”
“WCLC24 Highlight of this trip was catching up with my former Penn Medicine – Abramson Cancer Center cofellow Dr Marin Xavier Oncologist extraordinaire Scripps Health in San Diego and her family . The friendships you make along the way in medical trainning are special.”
“The amazing Narjust Florez presents Dana Farber Cancer Care Equity Program (CCEP)’s Lung Cancer Screening Initiative, making lung cancer screening smoking cessation services more accessible to vulnerable populations. CCEP enabled 85% of patients to complete 1st lung cancer screening!”
”Hot off the press.
Just published in Journal of Clinical Oncology in conjunction with presentation of overall survival data at IASLC WCLC24.
Results of TROPION-Lung01 Study of Datopotamab Deruxtecan Vs Docetaxel for Previously Treated Advanced NSCLC.”
Summary of key results of TROPION-Lung 01:
Modest increase PFS 4.4 vs 3.7 months (HR: 0.75)
PFS benefit was MAINLY in Non Squamous histology 5.5 vs 3.6 mo (HR: 0.63)
No PFS benefit in squamous histology
No OS benefit overall”
“It was great to finally meet Lucia Viola in person at WCLC24! She’s the next chair of the Multidisciplinary Care: Nursing, Allied Health and Palliative Care Track. Excited for what’s to come under her leadership!”
“WCLC24 Going on now plenary session on Exploring the Rising Influence on Non-Tobacco Risk Factors, chaired by Linda Martin and patient advocate Dave Bjork.
First presentation on the impact of Climate Change on lung cancer outcomes and incidence by Leticia Nogueira
We have 3 choices in climate change:
- Mitigation
- Adaptation
- Solutions
Next Clearing the Air: Unmasking Indoor Pollutants and Lung Cancer Risk by Roselle de Guzman from Manila.
- Air pollution is a global health issue
- many workers around the world still exposed to asbestos”
“Honored to have the opportunity to meet the legendary Tony Mok at WCLC24. His contributions to lung cancer research are truly inspiring!”
“No better way to start the day after a IASLC 50 year celebration than a fun quiz session on targets by
Stephen V Liu, Ben Solomon and Natasha Leighl. Guaranteed to be fun and instructive. Room 33!”
“Fantastic discussion yesterday with the Oncology Brothers and Oncology News Central on Lung Cancer management WCLC24! I’m excited to present a summary of insights from our outstanding panelists Estela Rodriguez and Eric K. Singhi on SCLC.”
“Important presentation on patient level data from CM816 and CM77T. As always, PatrickForde gave a great presentation. I do believe this is a unique dataset that can answer some questions about the adjuvant component of ‘sandwich’ strategies.”
“2 great presentations on novel ErbB2 TKIs- BAY2927088/zongertinib
- outstanding RR (up to 90% for key YVMA subset)
- fair tolerance
- signal of CNS activity
Main problem we might face…embarrassment of riches- between tdxd and these 2 exciting agents- which Her-bal therapy to choose?”
“PH3 Aumolertinib Maintenance after CRT LA NSCLC EGFR+ (POLESTAR) WCLC24: mPFS 16 vs 14 , 1-y PFS 69% vs 21%. Almost identical magnitud of benefit than LAURA (HR 0.2 and 0.16). Discussion by Fiona Hagi-Johnson recalls the need of implementing PET-CT for staging. OS pending.”
“Simply AMAZING group – great to see everyone. Proud to lead with Gilberto Lopes the IASLC Global Policy and Partnership Committee – keep an eye of our activities that will showcase the policy aspect in lung cancer.”
“Always a pleasure being with Gilberto Lopes – thank you so much for the terrific conversation! It was also a wonderful surprise to have Fabio Moraes join us!”
“Exciting news! In just six short weeks, 1000 people living with Lung Cancer have joined our research initiative! Help us find other people who may be interested by sharing this study today.”
“Just when we thought WCLC24 couldn’t get better… we got an incredible presentation and puppies! Our furry friends came along to help lift spirits. Definitely an impactful and adorable highlight of Day 3.”
“We need to keep repeating this over and over again. Thanks to Jill Feldman, EGFR Resisters
for this awesome picture. Well done to Chee Lee for raising this WCLC2024.”
“Love the message here – tolerability is not the same than safety
Jill Feldman impact is invaluable.”
“APOLO trial: an academic multicentric Spanish Lung Cancer Group presented by Mariano Provenicio at WCLC24: proof of concept of induction chemo-immunotherapy followed by radio-chemotherapy and Atezolizumab maintenance in unresectable Stage III NSCLC.”
“Excellent point by Pamela Samson that we need to get better at selecting the right patients for surgical management strategies for stage III NSCLC.”
“Great session on targeted therapies, with brilliant discussion by Jessica J Lin!
- Interesting STARLET pooled RCT analysis of osi with or without SRS for brain mets no significant PFS benefit with upfront SRS
- QOL data from KRYSTAL12 and PALOMA3, showing key role of PROs in trials WCLC24.”
“Starting now at IASLC WCLC24 Real World implementation of early lung cancer detection Narjust Florez discussing Bringing Equity to the Community the Dana Farber’s lung cancer screening initiative.”
“Zongertinib BEAMION-Lung01 pretreated HER2 TKD M+. 120Mg dose chosen. 65% YVMA. 1% g3 diarrhea. Low G3+ TRAEs. ORR 72.4%. Intracranial ORR 33% (RANO).
Another highly active HER2 TKI. Looking forward to future development.”
“Dr. William William discusses whether or not we should continue osi beyond progression-
Takeaways:
- retrospective data is suggestive, it’s inconsistent
- may not add CNS protection with chemo + amivantamab
- need prospective data”
“BEAMION: Zongertinib in HER2 mutation
- ORR 66.7%
- Best DCR = 94 – 100%
PFS + DoR immature
- Lower Gr3 diarrhoea than BAY2927088
- CNS activity, icRR = 33-40
-More favourable TRAE
-ORR similar to SOHO-01
-Need PFS data
-Ph3 ongoing”
“Excited to round out another great day at WCLC24 by leading a poster tour this evening. Come check out these posters in the evening poster session, highlighting the changing prognostic and predictive landscape in hard to treat thoracic malignancies.”
“CAR-T cell in Lung Cancer: Hope or Hype?
Some early data of good results: Further results awaited
Targets of CAR T include GPC3, DLL3, ROR1, CEA, even ALK and EGFR
Nice summary by Ben Creelan at WCLC24.”
“Safety and Efficacy of BAY 2927088 In Patients with HER2-Mutant NSCLC: Expansion Cohort from the Phase I/II SOHO-01 Study.
ORR: 72.1%, mPFS 7.5 months
In patients with YVMA ins: ORR 90% and mPFS 9.9 months
G3 or higher AEs 43.3%”
More posts about WCLC24 on oncodaily.com
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023